Panagene Signs Off with Dako to Supply PNA Oligomer Component
DAEJEON, South Korea--(BUSINESS WIRE)--Feb 22, 2013--Panagene announced it has signed a supply agreement with Dako Denmark A/S to supply PNA oligomer key component for incorporation into Dako’s diagnostic or research products. Dako, an Agilent Technologies Company since June 2012, is a leading global provider of tissue-based cancer diagnostic solutions. Under the agreement, Panagene will be the exclusive supplier of PNA probes which are raw materials for Dako’s diagnostic products.
PNA (Peptide Nucleic Acid) is an artificially synthesized DNA analogue which has higher binding affinity, specificity and sensitivity to the target and high biological/chemical stability. Panagene produce PNA probe of high quality and yield by its proprietary synthesis technology and has supplied its PNA probe to several multinational companies within in vitro diagnostics.
“We are pleased to manufacture and supply PNA probes to Dako for incorporation into their products. This agreement proves again that we are the world leader in the production of high quality PNA probes for research and diagnostic applications,” said Dr. Sung Kee Kim, President and CEO of Panagene.
Panagene is a worldwide custom PNA (peptide nucleic acid) oligomer provider, and has focused on developing various molecular diagnostic products based on PNA oligomers. With strong patent portfolio for manufacturing PNA products, Panagene succeed to commercialize diagnostic kits for somatic mutation and infectious disease. Compared with DNA-based diagnostic products, ones with PNA give higher sensitivity and stability.